Aarey Drugs & Pharmaceuticals is a family-run Indian company that makes a handful of specific Active Pharmaceutical Ingredients (APIs) - the chemical building blocks inside medicines - but its real scale comes from a parallel business importing and trading industrial chemicals and solvents on a massive scale. Incorporated in 1990 and steered by three generations of the Ghatalia family from a head office in Mumbai’s historic Masjid Bunder trading district, the company operates a single manufacturing plant in the Tarapur industrial zone while its trading desk buys chemicals from international markets and sells them into the domestic Indian market. The recurring approach is a dual-engine model where the company’s own factory produces a defined set of APIs and intermediates, while the trading arm - which has at times accounted for the entirety of the company’s turnover - provides the bulk of its revenue heft, with the two engines sharing the same balance sheet, working-capital lines, and family management.
Business segments
Two engines running on the same balance sheet - a small-batch API factory making three drugs and their chemical intermediates, and a high-volume import-trading desk that buys solvents and chemicals from abroad for the Indian market - both managed by the same family team out of a single Mumbai office.
1. Chemical and solvent trading: the volume engine that dominates the balance sheet
Importing chemicals and solvents and selling them into the Indian market is the activity that generates the overwhelming majority of the company’s revenue, making Aarey Drugs effectively a trading house with an attached factory.
- Imported, not just bought locally - the company’s own description of its business remained “Manufacturers of Bulk Drugs & Dealers of Chemical & Solvents” through April 2025, and it spent Rs. 11.08 crore in foreign exchange on purchases in FY25 alone, sourcing materials from international markets for domestic resale.
- Credit-heavy, balance-sheet-intensive - the trading cycle ties up significant capital: as of September 2025, trade receivables stood at Rs. 122.34 crore and inventories at Rs. 39.12 crore, with some receivables stretching beyond 180 days past due, indicating that extended credit terms to buyers are a structural feature of this business.
- Bank-funded working capital - the company finances its trading operations through secured working-capital limits exceeding Rs. 5 crore from banks, using its current assets as collateral, which is how it sustains the cash cycle of buying internationally and collecting from domestic customers later.
- A licence to trade almost anything - the company’s memorandum of association authorises it to deal in an extraordinarily wide range of goods - from chemicals and petroleum to textiles and electronics - giving the trading desk broad legal room to pivot across commodity categories as opportunities arise.
2. API and intermediate manufacturing: the own-product engine at Tarapur
A single plant in Maharashtra’s Tarapur industrial zone produces three specific APIs and five chemical intermediates, serving both Indian and export customers from a modest but steadily modernising factory.
- Three drugs, five intermediates - the factory makes Metformin HCL (a first-line diabetes drug), Mefenamic Acid (a pain and inflammation NSAID), and Doxophylline (a respiratory bronchodilator), plus five intermediates - Mono Methyl Urea, Die Methyl Urea, Ortho Para Nitro Anisole, 2 Bromomethyl 1,3 Dioxalane, and Uracile - that other pharma companies buy as building blocks for their own synthesis.
- Growing export reach from a single site - foreign-exchange earnings from exports on an FOB basis rose from Rs. 92.79 lakh in FY22 to Rs. 298.23 lakh in FY25, showing that the Tarapur plant’s output is finding buyers beyond India’s borders.
- Capacity being added, not just maintained - as of May 2023, the company had installed new plant and machinery at Tarapur that was fully in place but not yet commissioned, signalling an expansion or modernisation programme underway at the site.
- Workforce trained in-house - the company runs more than 15 internal training programmes each year for its manufacturing personnel, and industrial relations at the Tarapur plant have been consistently described as cordial across every annual report reviewed.
Group structure and partners
Aarey Drugs is a standalone, family-controlled listed company with no subsidiaries or joint ventures, but it operates within a tight web of promoter-owned private entities with which it shares directors, loans, and capital-raising transactions.
- No subsidiaries, no joint ventures - the company has consistently reported zero subsidiaries, holding companies, or associates across every annual report from FY20 through FY25, making it a pure standalone entity with no corporate layers beneath or above it.
- Capital raised from promoters, repeatedly - the company has undertaken multiple preferential issues of shares and convertible warrants directed at promoter-group entities, including a December 2024 approval for 50 lakh convertible warrants at Rs. 63.80 each allotted to 11 promoter entities and 6 non-promoter individuals, with an 18-month conversion window.